Non-Peptidic Small Molecule Inhibitors Against Bcl-2 for Cancer Therapy

被引:109
作者
Azmi, Asfar S. [2 ]
Mohammad, Ramzi M. [1 ]
机构
[1] Wayne State Univ, Sch Med, Dept Internal Med, Div Hematol & Oncol & Internal Med,Karmanos Canc, Detroit, MI 48201 USA
[2] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA
基金
芬兰科学院;
关键词
FAMILY PROTEINS; BH3; DOMAIN; CELL-DEATH; BH3-ONLY PROTEINS; ANTIMYCIN-A; IN-VIVO; APOPTOSIS; BAX; CHELERYTHRINE; BINDING;
D O I
10.1002/jcp.21567
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
A critical regulator of the apoptotic machinery is the Bcl-2 family proteins whose over expression confers a protective effect on malignant cells against death signals of apoptosis. Cancer cells that are resistant to various anti-cancer drugs and treatment regimen are found to over express these Bcl-2 proteins such as Bcl-2, Bcl-X-L, Mcl-1, Bcl-w, and AI/Bfl1. In recent years there has been an exponential growth in the identification as well as synthesis of non-peptidic cell permeable small-molecule inhibitors (SMIs) of protein-protein interaction. The focus of this article is on inhibitors of anti-apoptotic protein Bcl-2. This review summarizes an up to date knowledge of the available SMIs their mode of action as well as their current status in preclinical as well as clinical development.
引用
收藏
页码:13 / 21
页数:9
相关论文
共 81 条
[31]   Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax) [J].
Konopleva, Marina ;
Watt, Judie ;
Contractor, Rooha ;
Tsao, Twee ;
Harris, David ;
Estrov, Zeev ;
Bornmann, William ;
Kantarjian, Hagop ;
Viallet, Jean ;
Samudio, Ismael ;
Andreef, Michael .
CANCER RESEARCH, 2008, 68 (09) :3413-3420
[32]  
KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327
[33]   Role of Bcl-2 family proteins (Bax, Bcl-2 and Bcl-X) on cellular susceptibility to radiation in pancreatic cancer cells [J].
Lee, JU ;
Hosotani, R ;
Wada, M ;
Doi, R ;
Kosiba, T ;
Fujimoto, K ;
Miyamoto, Y ;
Tsuji, S ;
Nakajima, S ;
Nishimura, Y ;
Imamura, M .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (09) :1374-1380
[34]   Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics [J].
Letai, A ;
Bassik, MC ;
Walensky, LD ;
Sorcinelli, MD ;
Weiler, S ;
Korsmeyer, SJ .
CANCER CELL, 2002, 2 (03) :183-192
[35]   Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c [J].
Liu, XS ;
Kim, CN ;
Yang, J ;
Jemmerson, R ;
Wang, XD .
CELL, 1996, 86 (01) :147-157
[36]   Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program [J].
Lock, Richard ;
Carol, Hernan ;
Houghton, Peter J. ;
Morton, Christopher L. ;
Kolb, E. Anders ;
Gorlick, Richard ;
Reynolds, C. Patrick ;
Maris, John M. ;
Keir, Stephen T. ;
Wu, Jianrong ;
Smith, Malcolm A. .
PEDIATRIC BLOOD & CANCER, 2008, 50 (06) :1181-1189
[37]  
Mohammad R, 2002, CLIN CANCER RES, V8, P1277
[38]  
MOHAMMAD R, 2008, APOG2 POTENT NONTOXI
[39]   Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1 [J].
Mohammad, Ramzi M. ;
Goustin, Anton Scott ;
Aboukameel, Amro ;
Chen, Ben ;
Banerjee, Sanjeev ;
Wang, Guoping ;
Nikolovska-Coleska, Zaneta ;
Wang, Shaomeng ;
Al-Katibl, Ayad .
CLINICAL CANCER RESEARCH, 2007, 13 (07) :2226-2235
[40]  
Morris MJ, 2002, CLIN CANCER RES, V8, P679